2023 World Conference on Lung Cancer (Posters)-EP16.01. Optimizing Treatment Outcomes for L858R EGFR+ NSCLC

Pdf Summary

In a presentation at the WCLC 2023 conference, an advocate for patient rights discussed the treatment outcomes for patients with stage IV L858R EGFR NSCLC. Recent real-life data revealed that first-line treatment with the EGFR TKI Osimertinib resulted in a median overall survival of 17 months for patients in the Netherlands. However, resistance to EGFR TKIs is often inevitable, and chemotherapy and immunotherapy do not significantly improve outcomes and may come with serious side effects. <br /><br />The advocate proposed exploring alternative doses and schedules for EGFR TKIs, as the actual drug concentration in the blood varies among patients. If concentrations are too low, patients are at risk of disease progression, while higher concentrations can lead to more side effects. Currently, there are no studies investigating alternative doses for targeted therapies. <br /><br />The advocate shared the case of a patient with L858R EGFR NSCLC who has been taking a once-weekly dose of Afatinib at 240 mg for four years. This corresponds to six standard daily doses. The patient has experienced fewer side effects than on the standard daily dose of Afatinib. Additionally, pulsed Afatinib has been studied as a safe and tolerable alternative for certain EGFR mutations and brain metastases. <br /><br />The advocate called for a clinical trial of pulsed Afatinib to determine if this treatment approach could improve outcomes and potentially prolong overall survival and progression-free survival for patients with EGFR NSCLC. They emphasized the need for better and safer treatment options for these patients.

Asset Subtitle

Jo Monsen

Meta Tag

Speaker Jo Monsen

Topic Patient Advocacy

Keywords

WCLC 2023 conference

patient rights

treatment outcomes

EGFR TKI Osimertinib

resistance to EGFR TKIs

alternative doses

drug concentration

pulsed Afatinib

EGFR mutations

clinical trial